CEMI Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (27 Apr 2023 @ 16:00):

Chembio Diagnostics, Inc., together with its subsidiaries, develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or diagnose diseases...

Stats
Today's Volume	351 642
Average Volume	538 392
Market Cap	16.71M
EPS	$0 ( 2024-03-27 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.632
ATR14	$0.0250 (5.49%)

Insider Trading

Date	Person	Action	Amount	type
2023-03-11	Angelico Paul	Buy	29 333	Common Stock
2023-03-15	Angelico Paul	Buy	7 885	Common Stock
2023-03-15	Angelico Paul	Sell	2 843	Common Stock
2023-03-11	Angelico Paul	Sell	10 575	Common Stock
2023-03-11	Angelico Paul	Sell	29 333	Restricted stock units

INSIDER POWER
-90.41
Last 100 transactions
Buy: 781 277 \| Sell: 10 790 554

Volume Correlation

Long: 0.06 (neutral)

Short: 0.14 (neutral)

Signal:(58.078) Neutral

Chembio Diagnostics Inc Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Chembio Diagnostics Inc Correlation - Currency/Commodity

0.75
( moderate )

0.88
( strong )

0.00
( neutral )

0.68
( moderate )

-0.79
( moderate negative )

Chembio Diagnostics Inc Financials

Annual	2022
Revenue:	$48.34M
Gross Profit:	$9.76M (20.19 %)
EPS:	$-0.960

FY	2022
Revenue:	$48.34M
Gross Profit:	$9.76M (20.19 %)
EPS:	$-0.960

FY	2021
Revenue:	$47.82M
Gross Profit:	$13.32M (27.86 %)
EPS:	$-1.400

FY	2020
Revenue:	$30.45M
Gross Profit:	$6.58M (21.60 %)
EPS:	$-1.340

Financial Reports:

No articles found.

Chembio Diagnostics Inc Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Chembio Diagnostics Inc

Chembio Diagnostics, Inc., together with its subsidiaries, develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or diagnose diseases. The company offers tests for COVID-19, HIV and Syphilis, and Zika virus. It also develops tests for malaria, dengue, chikungunya, Chagas, ebola, leishmaniasis, lassa, marburg, leptospirosis, rickettsia, and Burkholderia diseases. The company sells its products under the STAT-PAK, SURE CHECK, STAT VIEW, and DPP trademarks, as well as sells its products directly through distributors to medical laboratories and hospitals, governmental and public health entities, non-governmental organizations, medical professionals, and retail establishments in the United States and internationally. It has collaboration agreements with Bill & Melinda Gates Foundation, The Paul G. Allen Family Foundation, The Oswaldo Cruz Foundation, and the Foundation for Innovative New Diagnostics, as well as U.S. government agencies, such as Centers for Disease Control and Prevention, the Biomedical Advanced Research and Development Authority of the U.S. Department of Health and Human Services, and the U.S. Department of Agriculture. Chembio Diagnostics, Inc. was founded in 1985 and is headquartered in Hauppauge, New York.